SH2D4B

Across TCGA pan-cancer cohorts, SH2D4B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SH2D4B data layer compared with 19 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SH2D4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SH2D4B expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

BRCA, BLCA, and SKCM are the cancer types where SH2D4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.680	0.925	.004	28	view →
BLCA	OS	Median	All	0.226	0.720	.009	18	view →
SKCM	DFS	Median	II,III,IV	1.000	0.217	.010	13	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
UCEC	DFS	Median	All	0.961	0.626	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SH2D4B–BRCA (OS)

Open the BRCA breakdown →